US stock · Healthcare sector · Drug Manufacturers—General
Company Logo

Bristol-Myers Squibb Company

BMYNYSE

70.36

USD
+0.21
(+0.30%)
After Hours Market
23.31P/E
9Forward P/E
1.16P/E to S&P500
150.237BMarket CAP
3.01%Div Yield
Upcoming Earnings
26 Oct
Shares Short
8/31/22
22.71M
Short % of Float
1.06%
Short % of Shares Outs.
1.06%
% Held by Insiders
0.07%
% Held by Institutions
79.69%
Beta
0.42
PEG Ratio
2.01
52w. high/low
80.59/53.22
Avg. Daily Volume
9.64M
Return %
Stock
S&P 500
1 year
16.41
(17.80)
3 years
39.55
23.21
5 years
11.60
45.98
Scale: |
High
Low
32.35
25.73
27.37
16.00
26.62
17.23
28.00
22.24
35.44
24.97
36.34
30.64
54.49
32.50
61.77
46.30
70.87
51.82
77.12
49.03
66.10
46.01
70.05
46.94
64.75
42.48
68.34
45.76
69.75
53.22
80.59
60.86
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
9.14
9.82
10.42
9.53
11.37
12.50
10.55
9.97
9.58
9.93
11.63
12.63
13.82
15.33
18.83
20.54
21.37
Earnings per share
0.81
1.10
2.65
5.38
1.81
2.18
1.17
1.56
1.21
0.94
2.67
0.61
3.01
2.02
(3.99)
3.11
3.01
FCF per share
0.66
1.17
1.40
1.69
2.37
2.63
3.83
1.83
1.58
0.61
0.98
2.57
3.06
4.24
5.89
6.75
6.47
Dividends per share
1.12
1.12
1.24
1.26
1.29
1.33
1.37
1.40
1.45
1.49
1.52
1.57
1.60
1.57
1.80
1.95
2.05
CAPEX per share
0.40
0.43
0.48
0.37
0.25
0.22
0.33
0.33
0.32
0.49
0.73
0.64
0.58
0.49
0.33
0.43
0.51
Book Value per sh.
5.10
5.36
6.19
7.52
9.17
9.39
8.16
9.22
8.96
8.56
9.68
7.14
8.59
30.26
16.75
15.95
15.57
Comm.Shares outs.
1,960
1,970
1,977
1,974
1,713
1,700
1,670
1,644
1,657
1,667
1,671
1,645
1,633
1,705
2,258
2,258
2,206
Avg. annual P/E ratio
29.8
26.1
8.1
4.0
14.1
13.2
28.5
28.2
43.3
68.3
23.8
93.6
19.1
24.9
(15.1)
20.2
23.3
P/E to S&P500
1.6
1.5
0.4
0.1
0.7
0.8
1.9
1.7
2.4
3.4
1.1
4.0
0.8
1.0
(0.4)
0.7
1.2
Avg. annual div. yield
4.7%
3.9%
5.8%
5.8%
5.0%
4.6%
4.1%
3.2%
2.8%
2.3%
2.4%
2.7%
2.8%
3.1%
3.0%
3.1%
3.0%
Revenue (m)
17,914
19,348
20,597
18,808
19,484
21,244
17,621
16,385
15,879
16,560
19,427
20,776
22,561
26,145
42,518
46,385
47,144
Operating margin
14.6%
18.2%
20.6%
30.5%
29.1%
31.3%
22.3%
17.9%
10.8%
10.4%
23.4%
16.6%
22.7%
22.6%
5.1%
15.9%
23.5%
Depreciation (m)
927
892
816
707
744
801
681
763
467
376
382
789
637
1,746
10,380
10,686
10,473
Net profit (m)
1,585
2,165
5,247
10,612
3,102
3,709
1,960
2,563
2,004
1,565
4,457
1,007
4,920
3,439
(9,015)
7,014
6,637
Income tax rate
23.1%
22.7%
24.1%
21.1%
25.7%
24.7%
(6.9)%
10.8%
14.8%
21.5%
23.8%
81.0%
17.1%
30.5%
(30.9)%
13.4%
12.8%
Net profit margin
8.8%
11.2%
25.5%
56.4%
15.9%
17.5%
11.1%
15.6%
12.6%
9.5%
22.9%
4.8%
21.8%
13.2%
(21.2)%
15.1%
14.0%
Working capital (m)
3,806
1,704
8,053
7,645
6,534
7,538
1,242
6,476
6,147
2,398
4,863
5,291
6,506
11,050
11,112
11,394
9,271
Long-term debt (m)
7,248
4,381
6,585
6,130
5,328
5,376
6,568
7,981
7,242
6,550
5,716
6,975
5,646
43,387
49,169
39,605
37,107
Equity (m)
9,991
10,562
12,241
14,843
15,713
15,956
13,623
15,154
14,852
14,266
16,177
11,741
14,031
51,598
37,822
36,006
32,600
ROIC
8.8%
13.1%
21.8%
38.2%
14.6%
16.6%
7.7%
10.5%
8.7%
7.3%
18.6%
4.3%
20.9%
3.5%
(7.2)%
8.0%
8.8%
Return on capital
8.6%
11.3%
22.2%
38.6%
15.4%
16.9%
5.5%
8.0%
7.6%
6.9%
18.0%
16.0%
17.6%
4.3%
(4.6)%
7.4%
8.0%
Return on equity
15.9%
20.5%
42.9%
71.5%
19.7%
23.2%
14.4%
16.9%
13.5%
11.0%
27.6%
8.6%
35.1%
6.7%
(23.8)%
19.5%
20.4%
Plowback ratio
(38.7)%
(2.2)%
53.1%
76.6%
29.0%
39.2%
(16.6)%
9.9%
(19.7)%
(58.3)%
42.9%
(155.9)%
46.9%
22.1%
145.2%
37.3%
32.0%
Div.&Repurch./FCF
157.3%
81.4%
88.8%
49.7%
62.1%
64.3%
66.1%
72.4%
80.5%
218.5%
158.8%
119.6%
58.8%
138.0%
- -
70.1%
89.6%
Capital Structure
27 Jul · 2022 | Q2
All numbers in millions
Total liabilities
$ 67,696
Total assets
$ 100,357
Long-term debt
$ 37,107
Cash and equiv.
$ 10,750
Goodwill
$ 20,446
Retained earnings
$ 24,217
Common stock
2,202
Enterprise Value
$ 176,594
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
15,393
16,450
16,966
Receivables
7,685
8,501
9,369
Inventory
4,293
2,074
2,095
Other
1,983
5,367
6,465
Current assets
29,354
30,192
33,262
Acc. Payable
2,445
2,713
2,949
Debt due
3,479
2,504
4,948
Other
12,380
13,863
13,971
Current liabilities
18,304
19,080
21,868
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
9.09%
24.05%
12.74%
Cash flow
14.55%
40.41%
28.23%
Earnings
(177.80)%
(45.37)%
(9.67)%
Dividends
7.88%
15.98%
8.45%
Book value
(4.80)%
63.94%
27.45%
Insider Trading
Type
Shares
Date
Caforio Giovanni
Sale
25,000
09/20/22
Caforio Giovanni
Sale
50,000
09/15/22
Powell Ann
Sale
25,000
09/14/22
Elkins David V
Exempt
121,214
09/13/22
Elkins David V
Sale
103,951
09/13/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
10,781
10,129
10,540
11,068
42,518
2021
11,073
11,703
11,624
11,985
46,385
2022
11,648
11,887
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
(0.34)
(0.04)
0.83
(4.44)
(3.99)
2021
0.90
0.47
0.68
1.06
3.11
2022
0.58
0.65
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.45
0.45
0.45
0.45
1.80
2021
0.49
0.49
0.48
0.49
1.95
2022
0.54
0.52
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Drug Manufacturers—General
CEO:
Dr. Giovanni Caforio
Full-time employees:
32,200
City:
New York City
Address:
430 E 29th St Fl 14
IPO:
Jul 5, 1929
Website:
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Recent News
· 26 Jul, 2022 · The Wall Street Journal
· 16 Oct, 2020 · The Wall Street Journal
· 6 Oct, 2020 · The Wall Street Journal
· 5 Oct, 2020 · The Wall Street Journal